[TABLE OF CONTENTS]

1 INTRODUCTION OF GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES

4 GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS

5 GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 PACEMAKERS
5.3 CARDIAC RESYNCHRONIZATION THERAPY
5.4 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
5.5 VENTRICULAR ASSIST DEVICES

6 GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY END-USER
6.1 OVERVIEW
6.2 HOSPITALS 
6.3 AMBULATORY SURGICAL CENTERS

7 GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY GEOGRAPHY
7.1 OVERVIEW

7.2 NORTH AMERICA

7.2.1 NORTH AMERICA MARKET SNAPSHOT
7.2.2 U.S.
7.2.3 CANADA
7.2.4 MEXICO

7.3 EUROPE

7.3.1 EUROPE MARKET SNAPSHOT
7.3.2 WESTERN EUROPE
7.3.2.1 THE UK
7.3.2.2 GERMANY
7.3.2.3 FRANCE
7.3.2.4 ITALY
7.3.2.5 SPAIN
7.3.2.6 REST OF WESTERN EUROPE
7.3.3 EASTERN EUROPE
7.3.3. 1 POLAND
7.3.3.2 RUSSIA
7.3.3.3 REST OF EASTERN EUROPE

7.4 ASIA PACIFIC

7.4.1 ASIA PACIFIC MARKET SNAPSHOT
7.4.2 CHINA
7.4.3 JAPAN
7.4.4 INDIA
7.4.5 AUSTRALIA & NEW ZEALAND
7.4.6 ASEAN
7.4.7 REST OF ASIA PACIFIC

7.5 MIDDLE EAST & AFRICA

7.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
7.5.2 UAE
7.5.3 SAUDI ARABIA
7.5.4 SOUTH AFRICA
7.5.5 REST OF MEA

7.6 SOUTH AMERICA

7.6.1 SOUTH AMERICA MARKET SNAPSHOT
7.6.2 BRAZIL
7.6.3 ARGENTINA
7.6.4 REST OF SOUTH AMERICA

8 GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET COMPETITIVE LANDSCAPE
8.1 OVERVIEW
8.2 COMPANY MARKET RANKING
8.3 KEY DEVELOPMENT STRATEGIES

9 COMPANY PROFILES

9.1 ABBOT LABORATORIES
9.1.1 OVERVIEW
9.1.2 FINANCIAL PERFORMANCE
9.1.3 PRODUCT OUTLOOK
9.1.4 KEY DEVELOPMENTS

9.2 ABIOMED INCORPORATED
9.2.1 OVERVIEW
9.2.2 FINANCIAL PERFORMANCE
9.2.3 PRODUCT OUTLOOK
9.2.4 KEY DEVELOPMENTS

9.3 BERLIN HEART GMBH
9.3.1 OVERVIEW
9.3.2 FINANCIAL PERFORMANCE
9.3.3 PRODUCT OUTLOOK
9.3.4 KEY DEVELOPMENTS

9.4 BIOTRONIK SE AND CO. KG
9.4.1 OVERVIEW
9.4.2 FINANCIAL PERFORMANCE
9.4.3 PRODUCT OUTLOOK
9.4.4 KEY DEVELOPMENTS

9.5 BOSTON SCIENTIFIC CORPORATION
9.5.1 OVERVIEW
9.5.2 FINANCIAL PERFORMANCE
9.5.3 PRODUCT OUTLOOK
9.5.4 KEY DEVELOPMENTS

9.6 JARVIK HEART INCORPORATED
9.6.1 OVERVIEW
9.6.2 FINANCIAL PERFORMANCE
9.6.3 PRODUCT OUTLOOK
9.6.4 KEY DEVELOPMENTS

9.7 LEPU MEDICAL
9.7.1 OVERVIEW
9.7.2 FINANCIAL PERFORMANCE
9.7.3 PRODUCT OUTLOOK
9.7.4 KEY DEVELOPMENTS

9.8 MEDTRONIC PLC
9.8.1 OVERVIEW
9.8.2 FINANCIAL PERFORMANCE
9.8.3 PRODUCT OUTLOOK
9.8.4 KEY DEVELOPMENTS

9.9 MICROPORT SCIENTIFIC CORPORATION
9.9.1 OVERVIEW
9.9.2 FINANCIAL PERFORMANCE
9.9.3 PRODUCT OUTLOOK
9.5.4 KEY DEVELOPMENTS

9.10 OSYPKA MEDICAL GMBH
9.10.1 OVERVIEW
9.10.2 FINANCIAL PERFORMANCE
9.10.3 PRODUCT OUTLOOK
9.10.4 KEY DEVELOPMENTS